ENDEAVOUR-VISION
22.4.2021 08:32:07 CEST | Business Wire | Press release
Endeavour Vision today announces the closing of Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices and high-net-worth individuals. EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies - 21 of which have exited via an acquisition or IPO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005851/en/
The fund’s closing comes as the world begins to look towards post-pandemic life after more than 12 months in the grip of COVID-19, a crisis that has accelerated the adoption of new healthcare technologies including novel ways of delivering remote patient care. Underlying trends, such as ageing populations, chronic diseases and strained healthcare budgets will continue to fuel demand for cost-efficient solutions. Therefore, healthcare innovation is set to remain a long-term priority that is expected to generate attractive growth and a diverse set of opportunities for investors. The fund has already supported seven companies with investments totalling more than USD 100 million: IntelyCare, CeQur, Rapid Micro Biosystems, SOPHiA GENETICS, Nalu Medical, Lumeon and Relievant Medsystems.
“Governments, citizens and investors are now more aware than ever of our healthcare systems’ strategic importance and current limitations,” said Bernard Vogel, Co-Founder and Managing Partner, Endeavour Vision. “This is accelerating the demand for pioneering solutions that can deliver sustainable healthcare. As such, EMG II LP’s timing could not be better. We want to thank the fund’s investors for their confidence in our team and strategy. In backing the bright future of this fast-growing, dynamic industry, our investors will also benefit from seeing the direct impact of their investments on people’s lives.”
“As a responsible investor working on behalf of UK Local Government Pension Schemes, we focus on seeking sustainable, long-term, risk-adjusted value to the pension scheme members through opportunities that provide a positive contribution to society,” said Nicholas Hinchliffe, Investment Director, Private Equity Investments, Local Pensions Partnership Investments. “Healthcare and health technology offers such an investment profile and helps diversify our client portfolios, and by investing in this vibrant sector through Endeavour Vision’s EMG II LP, we are able to access developments in ground-breaking clinical treatments.”
Endeavour Vision is one of the largest international investment teams focused on medtech and digital health. The firm partners with game-changing companies, actively supporting them beyond capital, with strategic and operational expertise to enable their global success.
“Medical technology and digital health are truly unique within the healthcare sector because they offer the opportunity to invest in companies in the early stages of commercialisation and before major value-inflection milestones, yet still at attractive valuations.” says Damien Tappy, President and Managing Partner, Endeavour Vision. “As recognised industry experts on both sides of the Atlantic, we are excited about the massive accelerated transformation of healthcare delivery over the next decade and the leading role Endeavour Vision can play in this.”
For more information about Endeavour Vision, please see our infographic . Two summaries are also available about EMG II LP fund and its current portfolio companies .
- Ends -
About Endeavour Vision
Endeavour Vision is a venture capital and growth equity firm founded in 2000, that invests in growth-stage medtech and digital health companies in Europe and the US. Its international investment teams are based in two global healthcare hubs in Geneva, Switzerland, and Minneapolis, US. For more information and a full list of portfolio companies, visit endeavourvision.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005851/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom